<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159429</url>
  </required_header>
  <id_info>
    <org_study_id>9796</org_study_id>
    <secondary_id>2017-A00554-49</secondary_id>
    <nct_id>NCT03159429</nct_id>
  </id_info>
  <brief_title>Nasal Ventilation Versus Voluntary Hypoventilation in the Rehabilitation of Hyperventilation Syndrome</brief_title>
  <acronym>RehabSHV</acronym>
  <official_title>Nasal Ventilation Versus Voluntary Hypoventilation in the Rehabilitation of Hyperventilation Syndrome: a Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to measure the effect (at 3 months) of dyspnea control
      rehabilitation with nasal ventilation versus standard rehabilitation, in dyspneic patients
      with hyperventilation syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2017</start_date>
  <completion_date type="Anticipated">August 5, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The included population will be randomized into two parallel groups. One group will be assigned the experimental intervention. The other group will be assigned standard care. Outcomes will be compared between the two randomized groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Given that the experimental and comparator interventions concern behaviour and exercises, it is not possible to blind participants.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Dyspnea at VO2max</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>Dyspnea measured at the first VO2max during a maximal cardio-pulmonary effort test. Dyspnea is measured using a visual analog scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to start of mouth-breathing during exercise test</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>The delay of onset of oral ventilation during walking and / or on ergocycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The SNOT22 questionnaire score</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>The SNOT22 questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation during isowork</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>(Ventilation equivalents V'E / V'O2 and V'E / V'CO2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PACO2 at rest</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>PAC02 = Partial pressure of carbon dioxide in arterial blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH at rest</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>pH at rest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaO2 at rest</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>PaO2 = Partial pressure of oxygen in arterial blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PACO2 at maximum effort</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>PAC02 = Partial pressure of carbon dioxide in arterial blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH at maximum effort</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>pH at maximum effort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaO2 at maximum effort</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>PaO2 = Partial pressure of oxygen in arterial blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breathing rates during excerise testing</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>breaths per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcutaneous oximetry</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>tcpO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distance walked during 6 minute walking test</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>Distance walked during 6 minute walking test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum rate of oxygen consumption</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>VO2max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum dyspnea values</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>Dyspnea is measured using visual analogue scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea threshold during exercise testing</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>Dyspnea is measured using visual analogue scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The slope of the equation VE=f(PETCO2)</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>VE = expiratory ventilation ; PETCO2 = end tidal carbon dioxide tension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PETCO2 value when VE = 0</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>VE = expiratory ventilation ; PETCO2 = end tidal carbon dioxide tension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the equation P0.1=f(PETCO2)</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>P0.1 = occlusion pressure; PETCO2 = end tidal carbon dioxide tension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea measured using the MRC scale</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>Dyspnea measured using the Medical Research Council scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nijmegen questionnaire score</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>Nijmegen questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF36 questionnaire score</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>SF36 questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VQ-11 questionnaire score</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>VQ-11 questionnaire score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAD questionnaire score</measure>
    <time_frame>Change between Day 0 and Day 90 +- 30</time_frame>
    <description>HAD questionnaire score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hyperventilation Syndrome</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this arm will participate in the new rehabilitation programme.
Intervention: Nasal breathing rehabilitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this arm will participate in the usual rehabilitation programme.
Intervention: Standard rehabilitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard rehabilitation</intervention_name>
    <description>The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing usual procedures, which include: maintaining a diary, breathing coordination excercises, voluntary control of breathing rate, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.</description>
    <arm_group_label>Comparator arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Nasal breathing rehabilitation</intervention_name>
    <description>The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing the experimental procedures, which include: maintaining a diary, evaluating nasal breathing by the nostril-alternating technique according to Anuloma Viloma Pranayama Yoga, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have given his / her free and informed consent and signed the consent

          -  The patient must be a member or beneficiary of a health insurance program

          -  The patient is available for 3 months of follow-up

          -  The patient has at least two of the following clinical symptoms consistent with
             hyperventilation sydrome: dyspnea, chest pain or pressure, visual blurring, dizziness,
             a sensation of abdominal swelling, tingling in the fingers, stiffness in the fingers
             or arms, tingling sensation around the mouth, cold or moist hands, tension or anxiety

          -  Resting hypocapnia defined by a PaCO2 &lt;38 mmHg and a normal O2 alveolo-arterial
             gradient D (A-a) O2

          -  Absence of significant obstructive or restrictive pathology according to respiratory
             function tests

          -  Absence of indirect signs of pulmonary arterial hypertension according to
             echocardiography

          -  Absence of alteration of gas exchange on maximum cardiopulmonary stress test
             (elevation of gradient D (A-a) O2 &gt; 35 mmHg at peak stress)

          -  At least 2 of the following criteria: (i) a Nijmegen questionnaire score &gt; 23, (ii)
             the recurrence of at least two common symptoms during the maximum cardiopulmonary
             stress test, (iii) delayed return of PETCO2 (partial pressure of end-tidal carbon
             dioxide) to its basal value (&gt; 5 minutes)

        Exclusion Criteria:

          -  The subject is participating in another study

          -  The subject is in an exclusion period determined by a previous study

          -  The subject is under judicial protection, or is an adult under any kind of
             guardianship

          -  The subject refuses to sign the consent

          -  It is impossible to correctly inform the subject

          -  The subject cannot fluently read French

          -  The patient is pregnant

          -  The patient is breastfeeding

          -  The subject has a contra-indication (or an incompatible drug association) for a
             treatment required during this study (a priori, there are no contra-indicated drugs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence Pourias Laborde, DE</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas Molinari, PhD</last_name>
    <phone>04.66.33.79.89</phone>
    <email>nicolas.molinari@inserm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dany Jaffuel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>November 24, 2017</last_update_submitted>
  <last_update_submitted_qc>November 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hypoventilation</mesh_term>
    <mesh_term>Hyperventilation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

